Search results for "Intramuscular"

showing 10 items of 64 documents

Motor Unit Firing Behaviour of Soleus Muscle in Isometric and Dynamic Contractions

2012

Introduction. Understanding the detailed control of human locomotion and balance can be improved, when individual motor units can be isolated and their firing rates followed in natural movement of large, fuctionally important muscles. For this reason the present study investigated the motor unit discharge rate (MUDR) in isometric and dynamic contractions of the soleus muscle. Methods: Eleven males performed isometric (10–100% MVC) and dynamic (10–40% MVC) plantar flexions. Intramuscular EMG was measured from Soleus with bipolar wire-electrodes and decomposed with custom built “Daisy” software. Results. The Soleus MUDR was significantly higher in concentric compared to isometric or eccentric…

AdultMalemedicine.medical_specialtyContraction (grammar)Anatomy and PhysiologyDynamicBiophysicslcsh:MedicineElectromyographyIsometric exerciseConcentricPhysical medicine and rehabilitationDiagnostic MedicineSoleusIsometric ContractionmedicineEccentricHumansBiomechanicsIsometricta315lcsh:ScienceMuscle SkeletalBiologyMusculoskeletal SystemSoleus muscleMotor NeuronsClinical NeurophysiologyIntramuscularMultidisciplinarymedicine.diagnostic_testChemistryElectromyographyMotor unitPhysicslcsh:Rfood and beveragesAnatomymusculoskeletal systemMotor unitelektromyografiaTorqueMedicinelcsh:Qmedicine.symptomMuscle contractionMuscle ContractionResearch Article
researchProduct

Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial

2019

###EgeUn###

AdultMalemedicine.medical_specialtyHerpes Zoster Vaccinemedicine.medical_treatmentvirusesVaccines Synthetic/administration & dosageHematopoietic stem cell transplantationPlaceboInjections IntramuscularTransplantation Autologous01 natural sciencesHerpes Zoster Vaccine/administration & dosage03 medical and health sciences0302 clinical medicineAutologous stem-cell transplantationAdjuvants ImmunologicInternal medicinehemic and lymphatic diseasesmedicineHumansSingle-Blind Method030212 general & internal medicine0101 mathematicsAdverse effectHospitalization/statistics & numerical dataProportional Hazards ModelsImmunocompromised hostintegumentary systembusiness.industryIncidence (epidemiology)010102 general mathematicsvirus diseasesGeneral MedicineMiddle AgedNeuralgia Postherpetic/prevention & controlTransplantationsurgical procedures operativeHerpes Zoster/epidemiologyhematopoietic stem cell transplantationoncologyincidenceFemaleZoster vaccinebusinessFollow-Up Studiesmedicine.drug
researchProduct

Botulinum toxin to avoid component separation in midline large hernias.

2020

Abstract Background The goal of our study was to compare results in patients with large midline incisional hernia using modified anterior component separation versus preoperative botulinum toxin and following Rives repair, with a focus on surgical site occurrences, possibility of fascial closure, duration of hospital stay, and hernia recurrence rate. Methods From to March 2016 to June 2019, a prospective comparative study was performed in 80 consecutive patients with large midline incisional hernias and hernia transverse diameters between 11 and 17 cm under elective hernia repair at our tertiary center. Two groups were analyzed prospectively: 40 patients with preoperative botulinum toxin ad…

AdultMalemedicine.medical_specialtyIncisional herniamedicine.medical_treatment030230 surgeryInjections Intramuscular03 medical and health sciences0302 clinical medicineSurgical sitePreoperative CaremedicineHumansIncisional HerniaHerniaIn patientProspective StudiesBotulinum Toxins Type AHerniorrhaphyAbdominal MusclesAgedSurgical repairbusiness.industryAbdominal WallMiddle AgedHernia repairmedicine.diseaseBotulinum toxinComponent separationHernia VentralSurgeryElective Surgical Procedures030220 oncology & carcinogenesisSurgeryFemalebusinessTomography X-Ray Computedmedicine.drugSurgery
researchProduct

Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, par…

2011

Medication-overuse headache (MOH) represents a severely disabling condition, with a low response to prophylactic treatments. Recently, consistent evidences have emerged in favor of botulinum toxin type-A (onabotulinum toxin A) as prophylactic treatment in chronic migraine. In a 12-week double-blind, parallel group, placebo-controlled study, we tested the efficacy and safety of onabotulinum toxin A as prophylactic treatment for MOH. A total of 68 patients were randomized (1:1) to onabotulinum toxin A (n = 33) or placebo (n = 35) treatment and received 16 intramuscular injections. The primary efficacy end point was mean change from baseline in the frequency of headache days for the 28-day per…

AdultMalemedicine.medical_specialtyNeurologyOriginalPain medicineClinical NeurologyBotulinum toxin type-APlaceboInjections Intramuscularlaw.inventionChronic MigraineRandomized controlled trialDouble-Blind MethodlawmedicineHumansBotulinum Toxins Type AAdverse effectMuscle SkeletalBotulinum toxin type-A; Medication-overuse headache; Prophylactic treatment; Migraine; Pericranial muscle tendernessMigraineAgedAnalgesicsbusiness.industrySkullHeadacheGeneral MedicineMiddle Agedmedicine.diseaseBotulinum toxinMedication-overuse headacheAnesthesiology and Pain MedicinePericranial muscle tendernessMigraineNeuromuscular AgentsAnesthesiaSettore MED/26 - NeurologiaFemaleNeurology (clinical)businessProphylactic treatmentmedicine.drugThe journal of headache and pain
researchProduct

Analysis of thiamine transporter genes in sporadic beriberi

2014

Abstract Objective Thiamine or vitamin B 1 deficiency diminishes thiamine-dependent enzymatic activity, alters mitochondrial function, impairs oxidative metabolism, and causes selective neuronal death. We analyzed for the first time, the role of all known mutations within three specific thiamine carrier genes, SLC19 A2, SLC19 A3 , and SLC25 A19 , in a patient with atrophic beriberi, a multiorgan nutritional disease caused by thiamine deficiency. Methods A 44-year-old male alcoholic patient from Morocco developed massive bilateral leg edema, a subacute sensorimotor neuropathy, and incontinence. Despite normal vitamin B 1 serum levels, his clinical picture was rapidly reverted by high-dose in…

AdultMalemedicine.medical_specialtySLC19 A- SLC25 A19SLC19 AEndocrinology Diabetes and MetabolismGene mutationBeriberimedicine.disease_causeMitochondrial Membrane Transport Proteinslaw.inventionBeriberilawInternal medicineGenotypemedicineThiamine transporterObjective: Thiamine or vitamin B1 deficiency diminishes thiamine-dependent enzymatic activity alters mitochondrial function impairs oxidative metabolism and causes selective neuronal death. We analyzed for the first time the role of all known mutations within three specific thiamine carrier genes SLC19 A2 SLC19 A3 and SLC25 A19 in a patient with atrophic beriberi a multiorgan nutritional disease caused by thiamine deficiency. Methods: A 44-year-old male alcoholic patient from Morocco developed massive bilateral leg edema a subacute sensorimotor neuropathy and incontinence. Despite normal vitamin B1 serum levels his clinical picture was rapidly reverted by high-dose intramuscular thiamine treatment suggesting a possible genetic resistance. We used polymerase chain reaction followed by amplicon sequencing to study all the known thiamine-related gene mutations identified within the Human Gene Mutation Database. Results: Thirty-seven mutations were tested: 29 in SLC19 A2 6 in SLC19 A3 and 2 in SLC25 A19. Mutational analyses showed a wild-type genotype for all sequences investigated. Conclusion: This is the first genetic study in beriberi disease. We did not detect any known mutation in any of the three genes in a sporadic dry beriberi patient. We cannot exclude a role for other known or unknown mutations in the same genes or in other thiamine-associated genes in the occurrence of this nutritional neuropathy.HumansThiamineGenePolymerase chain reactionGeneticsMutationNutrition and DieteticsbiologyMembrane Transport ProteinsThiamine Deficiencymedicine.diseaseAlcoholismEndocrinologyMutationbiology.proteinThiamineMutations
researchProduct

Persistent unilateral tibialis anterior muscle hypertrophy with complex repetitive discharges and myalgia

1992

Unilateral enlargement of the tibialis anterior muscle associated with complex repetitive discharges occurred over several months in two patients and was preceded by pain and numbness in the lower leg. Neuroradiologic investigations excluded a compressive radiculopathy, but pharmacologic and neurophysiologic studies suggested a neurogenic basis for the muscle hypertrophy. Botulinum toxin A injection into the hypertrophied muscles led to a decreased muscle volume and cessation of muscle pain.

AdultMalemyalgiamedicine.medical_specialtyBotulinum ToxinsAnterior tibial muscleMuscle volumemedicine.disease_causeInjections IntramuscularMuscle hypertrophyBotulinum toxin aMuscular DiseasesTibialis anterior musclemedicineHumansLegbusiness.industryMusclesHypertrophyMiddle AgedBotulinum toxinSurgeryAnesthesiaClostridium botulinumNeurology (clinical)medicine.symptombusinessmedicine.drugNeurology
researchProduct

Use of long acting injectable aripiprazole before and through pregnancy in bipolar disorder: a case report

2019

Abstract Background Long-acting injectable (LAI) antipsychotics for psychotic disorders provide advantages in treatment compliance, but data on their use in pregnancy are very limited. We present a clinical case of aripiprazole LAI use in pregnancy. Case presentation A 43-year-old woman diagnosed with bipolar disorder, with several relapses due to treatment interruption while trying to conceive. Finally, aripiprazole LAI treatment was planned by mutual agreement between doctor and the patient, who took aripiprazole LAI before and during pregnancy. She gave birth at 40 weeks to a 3500 g baby girl with no congenital malformations, who was healthy at 5 months after delivery. Conclusion As far …

AdultPediatricsmedicine.medical_specialtyTime FactorsBipolar disordermedicine.medical_treatmentvirusesAripiprazoleCase Report030226 pharmacology & pharmacyInjections IntramuscularAntipsychotic03 medical and health sciences0302 clinical medicineimmune system diseasesPregnancylcsh:RA1190-1270medicineHumansPharmacology (medical)Bipolar disorderAntipsychoticlcsh:Toxicology. PoisonsPharmacologyDosage FormsPregnancybusiness.industrylcsh:RM1-950Pregnancy Outcomevirus diseasesCongenital malformationsmedicine.diseasePregnancy ComplicationsLong actinglcsh:Therapeutics. PharmacologyTreatment interruptionLong-acting injectable aripiprazoleAripiprazoleFemaleClinical casebusinessmedicine.drugAntipsychotic AgentsFollow-Up StudiesBMC Pharmacology and Toxicology
researchProduct

Botox® for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection

2012

Purpose To test the efficacy, duration and safety of 100 U of botulinum toxin type A (BoNT/A) in women affected by idiopathic detrusor overactivity (IDO) and the effectiveness of subsequent injections. Methods In this double centre, prospective study con- ducted from March 2008 to March 2010, we selected women affected by IDO who failed to respond to various antimuscarinic agents, reported intolerable anticholinergic side-effects or contraindication to their use, also without any response to tibial stimulation. Medical history, physi- cal examination, standard urodynamic examination, uri- nalysis, urine culture, a 4-day voiding diary and a quality of life questionnaire were requested for al…

AdultReoperationurge incontinencemedicine.medical_specialtyUrge incontinenceidiopathic overactive bladderUrologyBotox Idiopathic overactive bladder Urge incontinence Idiopathic detrusor overactivity Botulinum toxin type AInjections IntramuscularBotox idiopathic overactive bladder urge incontinence idiopathic detrusor overactivity botulinum toxin type A.medicineHumansProspective StudiesBotulinum Toxins Type ADuration (project management)Safety effectivenessAgedBotoxUrinary Bladder Overactivebusiness.industryObstetrics and GynecologyCystoscopyGeneral MedicineMiddle Agedmedicine.diseaseSettore MED/40 - Ginecologia E Ostetriciabotulinum toxin type Aidiopathic detrusor overactivityTreatment OutcomeOveractive bladderFemalemedicine.symptombusinessBotulinum toxin typeArchives of Gynecology and Obstetrics
researchProduct

Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endo…

2003

OBJECTIVE: The present study aims at demonstrating the equivalence of the 28-day and 3-month formulations of triptorelin SR (sustained release) in terms of percentage of patients achieving castration levels of estradiol (<==50 pg/mL) 84 days after treatment initiation. DESIGN: A phase II, prospective, randomized, multicenter, open study was conducted in two parallel groups of women with endometriosis. SETTING: Academic hospitals. PATIENT(S): Seventy-two women with endometriosis. were treated with a single intramuscular injection of 3-month triptorelin SR, and 74 patients were treated with one intramuscular injection of 28-day triptorelin SR every 28 days for 3 months. INTERVENTION(S): As pa…

Adultmedicine.medical_specialtyTime Factorsmedicine.drug_classChemistry PharmaceuticalPopulationEndometriosisUrologyEndometriosisInjections IntramuscularDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled triallawRecurrenceestrogenmedicineHumanseducationGynecologyeducation.field_of_studyTriptorelin PamoateEstradiolDecapeptylbusiness.industryendometriositriptorelinObstetrics and GynecologyMedical castrationLuteinizing Hormonemedicine.diseaseTriptorelinLuteolytic AgentsCastrationReproductive MedicinechemistryEstrogenPharmacodynamicsFemaleFollicle Stimulating HormoneIntramuscular injectionbusinessmedicine.drugFertility and sterility
researchProduct

Ulipristal acetate versus leuprolide acetate for uterine fibroids

2012

A b s t r ac t Background The efficacy and side-effect profile of ulipristal acetate as compared with those of leuprolide acetate for the treatment of symptomatic uterine fibroids before surgery are unclear. Methods In this double-blind noninferiority trial, we randomly assigned 307 patients with symptomatic fibroids and excessive uterine bleeding to receive 3 months of daily therapy with oral ulipristal acetate (at a dose of either 5 mg or 10 mg) or once-monthly intramuscular injections of leuprolide acetate (at a dose of 3.75 mg). The primary outcome was the proportion of patients with controlled bleeding at week 13, with a prespecified noninferiority margin of −20%. Results Uterine bleed…

Adultmedicine.medical_specialtyUterine fibroidsIntention to Treat AnalysiUrologyAdministration OralEndometriumInjections Intramuscularlaw.inventionchemistry.chemical_compoundYoung AdultEndometriumPrimary outcomeRandomized controlled trialDouble-Blind MethodlawUlipristal acetateSelective progesterone receptor modulatormedicineUterine NeoplasmUlipristalMenorrhagiaGynecologyIntention-to-treat analysisLeiomyomabusiness.industryObstetrics and GynecologyUterine bleedingUterine fibroids uterine leiomyomas uterine bleeding ulipristal acetate leuprolide acetate medical therapyGeneral MedicineNorpregnadieneMiddle Agedmedicine.diseaseSettore MED/40 - Ginecologia E Ostetriciamedicine.anatomical_structurechemistryAmenorrheaFemalemedicine.symptomLeuprolidebusinessHuman
researchProduct